INTRODUCTION
============

Malaria is an infectious disease caused by the protozoan parasite *Plasmodium* and transmitted by the *Anopheles* mosquitoes. Malaria is a major public health problem, leading to high mortality and morbidity. Nearly half the world's population is at risk of contracting malaria ([@B20]). There are 207 million cases of clinical malaria and approximately 627,000 deaths in [@B109]. There is currently no available vaccine. Age and host immune status are high risk factors for malaria, with young children under the age of five, pregnant women and travelers or migrants who lack immunity to the disease being most susceptible. Other risk factors include the infectivity and the transmission dynamics of the parasite strain ([@B28]).

The *Plasmodium* parasite has a complex life cycle. Following an infected mosquito bite, sporozoites are inoculated into the dermis of the mammalian host ([@B108]; [@B3]). The sporozoites travel to the liver *via* the bloodstream and infect the hepatocytes ([@B3]). During this phase in the hepatocytes, sporozoites develop into schizonts over 2--14 days, depending on the species. Merosomes, merozoites containing vesicles, eventually bud out from infected hepatocytes to release merozoites, which then infect erythrocytes ([@B100]; [@B8]). Some of the blood stage parasites undergo sexual differentiation into male and female gametocytes that can be taken up by a feeding Anopheline during a blood meal. Ookinetes, which results from gametocyte fusion, develop into oocysts in the midgut of the mosquito. Upon oocyst maturation, newly formed sporozoites migrate to the salivary gland of the mosquito, awaiting the next blood meal ([@B70]).

Symptoms of malaria include fever, headache, chills, sweating, and vomiting. Recurrent fever is one of the hallmarks of clinical malaria. This is a consequence of the release of malarial toxins into the bloodstream following repetitive rupture and re-invasion of erythrocytes. With disease progression, the red blood cell counts decreases and severe anemia might occur. Malarial infected red blood cells, such as those of *Plasmodium falciparum*, can also sequester in deep tissues, causing cerebral malaria, and organ failure. These severe pathologies can eventually lead to death.

IMMUNE RESPONSES TO A MALARIA INFECTION
=======================================

Protective immunity against malaria requires a timely and coordinated interplay between the innate and adaptive immunity. This involves dendritic cells, NK cells, B cells, CD4^+^ and CD8^+^ T cells ([@B99]).

Sporozoite-specific antibodies can block sporozoites from migrating to the liver or from invading into hepatocytes, arresting disease progression ([@B79]; [@B35]). Antibody-mediated immunity has been thought to be the central effectors of parasite clearance in the peripheral blood as MHC class I/II molecules are absent on the surface of infected red blood cells ([@B60]). The importance of antibodies was first demonstrated by [@B24], showing that passive transfer of immunoglobulins from immune adults into naïve, infected children resulted in rapid reductions of parasite density and resolution of clinical symptoms ([@B24]). Merozoite-specific antibodies can prevent merozoites from invading erythrocytes ([@B68]; [@B32]; [@B50]) and mediate clearance of infected red blood cells by phagocytic cells *via* antibody-dependent cellular inhibition ([@B66]). Pathogen-specific antibodies secreted by B cells with CD4^+^ T helper cells enhancement are essential for clearance of parasitemia in the later stages of the infection ([@B60]).

In addition to the humoral arm of the adaptive immunity, cell-mediated immune responses are also crucial for protection against malaria. CD8^+^ and CD4^+^ T cells kill infected hepatocytes through diverse mechanisms ([@B80]; [@B29]; [@B37]; [@B106]; [@B23]) and induce sterile protection (i.e., no blood stage infection) in mouse models. Recent work has revealed an important role for IFNγ-secreting CD8^+^ T cells in preventing chronic *P. chabaudi* blood stage infection in mice ([@B49]). In human, sterile protection has been observed in experimental sporozoite challenge experiments following vaccination with whole sporozoites ([@B48]; [@B89]; [@B92]). Both sporozoite-specific antibodies and T cells were induced.

VACCINE DEVELOPMENT AGAINST MALARIA
===================================

The rationale for vaccine development to protect against malaria stems from observations where naturally acquired immunity to malaria can protect individuals living in malaria-endemic regions against malaria in an age-dependent and exposure-dependent manner ([@B44]; [@B91]; [@B25]). Although the protection is not sterilizing and is not always ensured for all chronically exposed individuals, passive transfer of sera from some chronically exposed individuals reduced strongly parasite levels in infected individuals ([@B24]; [@B15]). This demonstrated that antibodies can offer protection against the blood phase of the malarial infection.

More rationally, the typical Pasteur approach where attenuated parasites were used as vaccines has further demonstrated the feasibility of vaccination as protection against malaria. Immunization with irradiation-attenuated sporozoites has shown to confer sterile immunity against sporozoites challenge in animal models and in humans ([@B85]; [@B72]; [@B22]; [@B86]; [@B48]). The protective immune response involving antibodies and T cells was shown to target the pre-erythrocytic stages ([@B72]; [@B76]). In recent years, immunization with sporozoite or blood parasite under drug cover was also shown to confer strong protective immunity involving antibodies and T cells ([@B12]; [@B81]; [@B89]; [@B38]). Other approaches have used genetically attenuated parasites. Although these approaches have led to sterile immunity in mice ([@B71]; [@B18]), they have yet to prove their efficacy in humans ([@B96]).

After decades of efforts spent on developing vaccines against malaria, no strong vaccine candidate has emerged as yet. Most vaccine development efforts are focused on only four antigens ([@B109]). The most clinically advanced candidate, RTS,S, conferred \~50% protection from clinical *P. falciparum* malaria in children aged 5--17 months, and \~30% protection in children aged 6--12 weeks ([@B2], [@B1]). Vaccine efficacy was undetectable 3 years after vaccination ([@B11]). This level of protection is suboptimal and too low to achieve malaria eradication. No single molecular signature, key cellular determinant or immune mechanism of naturally acquired or vaccine-induced immunity has been unequivocally associated with protection ([@B73]). This impediment toward vaccine development for malaria is multi-factorial. The *Plasmodium* parasite has a diverse protein repertoire, and a complex life cycle involving both vertebrate and invertebrate hosts. There are antigenic polymorphisms and variations across parasite strains and species, and the parasite has developed sophisticated strategies to evade the host immunity.

With more reports of drug resistance and insecticide resistance in some endemic regions ([@B104]; [@B77]; [@B7]), management of the malarial disease has been increasingly difficult. Identification of new malarial antigens for vaccine development is critical. Here, we reviewed the different techniques that have been used to identify antigens recognized by antibodies induced during natural infections or after vaccinations with whole parasites.

PRE-GENOMIC SCREENING METHODS FOR PROTECTIVE ANTIGENS
=====================================================

The advent of new molecular biology techniques in the 1980s led to the discovery of many *Plasmodium* antigens. DNA libraries, consisting of cDNA or genomic DNA, were constructed in bacteriophage vectors for expression in *Escherichia coli* ([@B56]). Antigens such as the circumsporozoite protein (CSP), the S-antigen, the ring erythrocyte surface antigen (RESA) were the first to be identified using mouse monoclonal antibodies ([@B33]), sera from infected humans ([@B55]; [@B98]) or sera from infected mice or monkeys ([@B5]; [@B17]; [@B6]). All the antigens discovered using these approaches were immunodominant or possessed immunodominant regions made of repeats ([@B54]). Although immunodominant antigens induce very strong antibody responses, recent studies have shown that they did not offer adequate protection when tested as subunit vaccines in clinical trials ([@B97]; [@B28]; [@B93]), suggesting that these antigens might be used by the *Plasmodium* parasite for immune evasion ([@B4]; [@B88]). The CSP, an antigen of pre-erythrocytic stage malaria and the first malaria antigen to be cloned ([@B33]), is one such example. Despite being immunodominant, the Phase III vaccine efficacy was suboptimal, with 55% reduction in the frequency of malaria episodes during the 12 months of follow-up in children 5--17 months of age and 35% in children 6--12 weeks old at first immunization ([@B2]). The protection waned to a mere 16.8% after 4 years of follow-up, indicating the lack of long lasting protection which declined with time and exposure to the parasite ([@B74]). Similarly, while immunization with the apical membrane antigen-1 (AMA-1), an antigen expressed both at the pre-erythrocytic and erythrocytic stages and strongly immunodominant during the erythrocytic stage, elicited functional antibodies with *in vitro* inhibition against homologous blood parasites, volunteers developed parasitemia upon challenge with controlled human malaria infection (infection by mosquito bites) without a significant reduction of peak parasitemia nor delay to patency ([@B97]).

The cDNA library approach is advantageous with a good representation of a stage-specific *Plasmodium* proteome, depending on the stage of the parasite at which the RNA was extracted from. However, the repertoire of the *Plasmodium* proteome the cDNA library represents is not entirely comprehensive and does not include antigens expressed by the parasite in the other stages of its life cycle. Nevertheless, it has successfully identified more than a hundred malaria antigens. Recently, [@B78] created a *P. falciparum* blood stage cDNA library constructed in bacteriophage and expressed in *E. coli*. The antigen library was screened against sera from either infection-resistant or -- susceptible chronically exposed individuals living in malaria-endemic regions. 2 out of 3 antigens identified were novel antigens. Antibody to one of the identified novel antigens, PfSEA-1, inhibited parasite growth and blocked schizont egress. Using the *P. berghei* ANKA strain ortholog of PfSEA-1, the authors demonstrated reduced parasitemia and longer survival in mice vaccinated with PbSEA-1. They further validated PfSEA-1 as a promising vaccine candidate through epidemiological studies, where anti-PfSEA-1 antibodies were strongly associated with lesser incidence of severe malaria in Tanzanian children and lower level of parasitemia in Kenyan adults.

SCREENING METHODS TO IDENTIFY NEW ANTIGENS IN THE ERA FOLLOWING GENOME SEQUENCING
=================================================================================

At the turn of the 20th century, whole genomes of many *Plasmodium* strains were sequenced. These genome sequencing initiatives, by The Wellcome Trust Sanger Institute and The Institute for Genomic Research, have provided a wealth of data for the identification of protective antigens ([@B19]; [@B39]). In this review, we discuss the novel approaches (summarized in **Table [1](#T1){ref-type="table"}**) to screen libraries of malarial antigen using sera from protected versus unprotected individuals to identify antigens associated with protection, in search for new protective antigens for vaccine development against malaria.

###### 

Approaches taken to identify protective malarial antigens for vaccine development.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     Type of antigen library              Antigen expression system                              Size of library    Type of screening                                Sera/antigens that library is screened against                                                                  Reference
  ------------------ ------------------------------------ ------------------------------------------------------ ------------------ ------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ------------------------
  Pre-genomic era    cDNA                                 *E. coli* cell-based                                                      *In vitro* immunoscreen                          Mouse monoclonal antibodies                                                                                     [@B33]

                     cDNA                                 *E. coli* cell-based                                   10 000 clones      *In vitro* immunoscreen                          Sera from infected human individuals                                                                            [@B55], [@B17], [@B98]

                     cDNA                                 *E. coli* cell-based                                   10 000 clones\     *In vitro* immunoscreen                          Sera from infected mice,\                                                                                       [@B17]\
                                                                                                                 10 000 clones\                                                      mice and rabbits,\                                                                                              [@B5]\
                                                                                                                 9 000 clones                                                        monkeys\                                                                                                        [@B6]

  Post-genomic era   cDNA                                 *E. coli* cell-based                                   1 250 000 clones   *In vitro* immunoscreen                          Sera from infection-resistant and --susceptible chronically exposed human individuals                           [@B78]

                     Recombinant proteins                 *E. coli* cell-free *in vitro* translation             250 antigens       *In vitro* immunoscreen                          Sera from protected and non-protected individuals following vaccination with radiation-attenuated sporozoites   [@B30]

                     Recombinant proteins                 *E. coli* cell-based and wheat germ cell-free system   46 antigens        *In vitro* immunoscreen                          Sera from malaria-exposed children                                                                              [@B84]

                     Antigens expressed on cell surface   Mammalian cell-based                                   80 antigens        *In vitro* immunoscreen                          Sera from protected and non-protected individuals following vaccination with live sporozoites                   [@B21]

                     Whole parasite lysates               *P. yoelii* parasite                                   Whole proteome     *In vitro* immunoscreen                          Affinity-purified IgG from immune mice that naturally survived a lethal infection                               [@B51]

                     DNA (exons)                          --                                                     19 genes           *In vivo* screen in mice for protection          --                                                                                                              [@B45]

                     Recombinant proteins                 Mammalian cell-based                                   51 antigens        *In vitro* protein--protein interaction screen   Malarial antigen, PfRh5                                                                                         [@B26]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NEW APPROACHES TO SEARCH FOR ANTIGENS INVOLVED IN PROTECTION
============================================================

The availability of whole genome sequences has enhanced the understanding of the parasite biology. Protein functions can be predicted and validated. Potential antigens could be screened for specific characteristics such as surface expression. Comparative genomics between different parasite strains allows identification of antigens that have limited variation, with the promise of greater vaccine coverage and hence efficacy in the field ([@B58]).

Transcriptomics and proteomics has provided critical information on the expression profiles of malarial proteins during the parasite's life cycle ([@B36]; [@B62]; [@B16]; [@B46]) -- the mosquito stage ([@B63]), the liver stage ([@B102]), and the sexual stage ([@B61]; [@B57]). *In silico* analysis of stage-specific transcription pattern identifies antigens that are differentially expressed for specific targeting to a specific stage of the parasite's life cycle and also antigens with conserved expression across the different stages for cross-stages targeting ([@B36]).

SCREENING RECOMBINANT PROTEIN MICROARRAYS AGAINST IMMUNE SERA FROM VACCINATED HUMAN INDIVIDUALS
-----------------------------------------------------------------------------------------------

Using the published *P. falciparum* and *P. vivax* genomes, a set of selected genes was targeted for protein expression using an *in vitro* transcription/translation system ([@B30]; [@B107]; [@B25]; [@B9]; [@B105]; [@B69]; [@B10]; [@B64]). These recombinant proteins were then printed onto microarray chips and probed with immune sera that were obtained from human volunteers naturally exposed to malaria infections or immunized with radiation-attenuated sporozoites. [@B30] generated a protein microarray with 250 *P. falciparum* proteins and used it to profile antibody responses in sera from four groups of individuals: (1) protected, (2) non-protected individuals following vaccination with radiation-attenuated sporozoites, (3) partially protected individuals due to natural exposure, and (4) non-exposed individuals. The same group then expanded their library to include 1204 *P. falciparum* proteins (representing 23% of the *P. falciparum* genome; [@B25]; [@B105]; [@B10]) and also 91 *P. vivax* proteins ([@B69]). 22--29% of the screened proteins were found to be serodominant in immune sera, demonstrating a broad and varied response to many antigens. Antibody titres against current vaccine candidates such as CSP, atypical membrane antigen-1, liver stage antigen-3, merozoite surface protein-1 did not differ between immune and non-immune individuals ([@B25]; [@B105]).

[@B84] expressed *P. falciparum* merozoite proteins, reported to have a role in erythrocyte invasion and/or localized on the merozoite surface or in the invasion organelles of the merozoites, in either bacterial or wheat germ cell-free expression systems. The recombinant proteins were tested for IgG immunoreactivity using sera from malaria-exposed Papua New Guinea children in ELISA. Forty six proteins were selected based on their ability to coat ELISA plates and their immunoreactivity. Sera from older children had higher immunoreactivity to most of the 46 proteins as compared to the younger children, indicating an acquisition of antibody responses with age, presumably due to prolonged exposure to the parasite. While merozoite surface proteins had higher seropositivity compared to the rhoptry and micronemal proteins, the antigens strongly correlated with protection were the rhoptry and micronemal proteins. This is consistent with other studies, suggesting that the key protective malarial antigens are the non-immunodominant antigens ([@B31], [@B30]; [@B25]; [@B105]; [@B10]). The authors proposed that a combinational vaccine consisting of non-immunodominant antigens, such as EBA, PfRh2 and PfRh4, is more likely to offer greater protection ([@B84]).

One of the main drawbacks with protein array is the extensive efforts needed to generate the soluble recombinant malarial antigens in the library ([@B30]; [@B107]). Cell-based expression systems have met with many difficulties. *P. falciparum* genes have a high A/T content and a substantial number of the genes encode stretches of repeat sequences ([@B39]), hindering protein expression in cell-based expression system. Only 30% out of 1000 genes investigated by [@B67] can be expressed in *E. coli* and a mere 6.3% of the proteins are soluble. The alternative is the wheat germ cell-free expression system. [@B107] were able to express 93 out of 124 *P. falciparum* genes as soluble proteins using the wheat germ cell-free system. [@B90] reported greater immunogenicity of wheat germ proteins (as opposed to identical proteins produced in *E. coli*) in mice. The wheat germ cell-free expression system could be more suitable for producing antigens for vaccine development.

SCREENING CELL-ASSOCIATED ANTIGEN LIBRARIES AGAINST IMMUNE MOUSE SERA
---------------------------------------------------------------------

We recently cloned a library of 80 malarial antigens into a mammalian surface expression vector pDisplay (Invitrogen; [@B21]). They transfected these expression vectors into mammalian cells and the antigens were expressed on the cell surface, creating a library of antigen-presenting cells. The library was screened against immune and non-immune sera obtained from mice immunized with live sporozoites or blood parasites under drug cover ([@B13]). Similarly, all immunized volunteers in the study were protected from sporozoites challenge. The antibody repertoire of immunized volunteers was extremely broad and varied. MAEBL was found to be strongly associated with protection. MAEBL has been implicated in invasion into hepatocytes by sporozoites and merozoites into erythrocytes ([@B53], [@B52]). It was previously demonstrated that anti-MAEBL antibodies to inhibit *P. yoelii* sporozoites invasion *in vitro* in primary mouse hepatocytes, suggesting that MAEBL is a promising attractive vaccine candidate ([@B95]).

This approach removes the difficulty of expressing and purifying antigens as soluble recombinant proteins. However, the library size in this study represents a small representation of the entire *Plasmodium* genome (\~1%) and antigens screened were mainly restricted to those with reasonably good transfection efficiency.

SCREENING WHOLE PARASITE LYSATES AGAINST AFFINITY-PURIFIED IgG FROM NATURALLY SURVIVING MICE
--------------------------------------------------------------------------------------------

Due to ethical and technical restrictions, identification of protective immune correlates in humans can only be evaluated in the peripheral blood component. This hinders the study of a vital stage of the parasite's life cycle, the liver stage. It also limits the examination of the host immune responses in the secondary lymphoid organs such as the spleen, which are also important sites for the induction of protective immunity.

The use of comparative genomic analysis, through the construction of genome-wide synteny maps, has identified other non-human models of malaria ([@B19]; [@B101]). Mouse models have played a vital role in the understanding of the immunobiology of malarial infections. The mouse malaria parasite, *P. yoelii*, has been used as a model for malaria research due to the substantial similarity to the human parasite *P. falciparum* ([@B47]). In addition to being cheaper to maintain and easier to handle, the mouse also has a well characterized immune system, hence offering great advantages over non-human primate models ([@B110]; [@B103]). Infection studies of rodent malaria species and their hosts have provided information on parasite biology and pathogenicity. Identification of orthologs allows preclinical validation of new chemotherapies and vaccine candidates. The lethal *P. yoelii* model, which causes death in BALB/c mice, is an excellent model for investigating the vaccine efficacy of the candidates *in vivo* ([@B59]). [@B51] observed that 20% of ICR mice infected with the lethal strain of *P. yoelii* cleared the infection and these naturally surviving mice had boosted immunity following a second challenge. They affinity-purified the IgG from these mice and probed against whole parasite lysates. Using MALDI-TOF analysis, the antigenic specificities of the protective IgG were Heat shock protein 70 (HSP70), protein disulphide isomerase, plasmepsin and a 39 kDa subunit of eukaryotic translation initiation factor 3. Although the authors did not validate the protective potential of the identified antigens, the approach used in the study identified novel antigens (with the exception of PfHSP70.1 ([@B45]). Antibodies against PfHSP70.1 have been shown to eliminate *in vitro* liver stage parasites through antibody-dependent cell-mediated cytotoxic mechanisms ([@B83]).

SCREENING FOR PROTECTIVE DNA VACCINE CANDIDATE IN MOUSE CHALLENGE MODEL
-----------------------------------------------------------------------

New molecular technologies such as Gateway cloning make it easy to clone large numbers of genes into plasmids. Using this technology, [@B45] produced an expression library of 182 *Plasmodium* exons coding for pre-erythrocytic antigens in the mammalian immunization vector VR1012. They immunized mice with 19 out of the 182 cloned vectors, either singly or in combination, and assessed vaccine efficacy following sporozoites challenge by examining the ability of the immunized mice to reduce liver stage parasite load. The most promising DNA vaccine candidate identified was Py01316, annotated as a Qa-SNARE protein in PlasmoDB, which gave a 68--79% reduction in parasite load.

The approach taken by [@B45] has the benefit of generating a library of DNA vaccine candidates, targeting many *Plasmodium* genes with great ease, and does not require the laborious process of generating recombinant proteins. It also provides information on the immunogenicity of the DNA constructs and *in vivo* effectiveness of the induced immune responses to reduce parasite load. However, screening for protective DNA vaccine targets in mice is laborious and requires a large number of mice. As a result, the authors screened a total of 19 out of the 182 cloned plasmids, which limited the number of malarial antigens that can be validated for protective efficacy.

TARGETED SCREENING TO IDENTIFY MALARIAL ANTIGENS AND THEIR RECEPTORS
--------------------------------------------------------------------

[@B26] expressed a library of erythrocyte surface proteins with the mammalian expression system. Using the avidity-based extracellular interaction screen (AVEXIS), they screened recombinant PfRh5 protein (the bait protein), which is critical for erythrocyte invasion by merozoites, against the library of erythrocyte surface proteins (the prey protein). The PfRh5 protein was found to interact with only one erythrocyte surface protein, basin. The anti-basin monoclonal antibodies were highly effective at blocking *P. falciparum* invasion into erythrocytes *ex vivo* and these blocking effects were efficacious with 15 other culture-adapted and field strains of *P. falciparum*. These data have implications for novel therapeutics. While this does not directly identify new protective malarial antigens for vaccine development, the identification of basin as the binding partner of PfRh5 and perhaps further characterisation studies on the expression levels of basin by the target population would provide critical information on the vaccine efficacy of PfRH5, should PfRh5 be developed as a vaccine candidate. Understanding how basigin binds to PfRh5 could also facilitate rational design of drug compounds to block *P. falciparum*'s invasion into erythrocytes.

One of the shortcomings of AVEXIS is the generation of the library of recombinant proteins, which is laborious. This approach also requires the prior identification of a known bait protein, which is difficult for identifying novel host--parasite interacting antigen pairs. However, the AVEXIS assay is advantageous in its ability to detect direct low-affinity protein interactions, which might not be detectable in other screening methods. More recently, this type of library has shown to be a powerful tool to identify new protective antigens for potential vaccine target development. Using sera from a longitudinal study in a cohort of Kenyan children, [@B75] identified 10 antigens (PF3D7_1136200, MSP2, RhopH3, P41, MSP11, MSP3, PF3D7_0606800, AMA1, Pf113, and MSRP1) that were associated with protection against clinical episodes of malaria. While the AVEXIS approach has been used to identify blood stage antigens in this study, the study could be extended to include antigens for other stages.

IDENTIFICATION OF PROTECTIVE PRE-ERYTHROCYTIC ANTIGENS
------------------------------------------------------

Pre-erythrocytic antigens have been attractive targets for vaccine development. This is mainly due to the demonstration that sterile immunity against malaria is achievable in experimental sporozoite challenge experiments in humans following vaccination with whole sporozoites ([@B48]; [@B89]; [@B92]).

Most of the above described approaches for identification of protective antigens have used sera from chronically exposed individuals living in endemic regions to screen for protective malarial antigens. Although the approaches have identified mainly blood stage antigens, some of the identified blood stage antigens, such as AMA1 ([@B94]), TRAP ([@B87]), EBA175 ([@B41]), PfEMP3 ([@B40]), and HSP70.1 ([@B82]), which are also expressed during the liver stage.

To screen for protective pre-erythrocytic antigens, it is essential to have the appropriate sera sets against which the library of malarial antigens will be screened. While sera from chronically exposed individuals living in endemic regions are relatively easier to obtain, they are more likely to have an antibody repertoire that is predominantly specific for blood stage antigens, hence might not be suitable for the identification of liver stage antigens. [@B65] and [@B42] were the first to show in human that chloroquine prophylaxis protected against blood stage infection and use the protected sera to screen for protective antigens. This led to the identification of liver-specific (LSA1; [@B43]) or cross stage-specific antigens stages (LSA-3, STARP, and SALSA; [@B34]; [@B14]; [@B27]). Recently, the studies by [@B105] and [@B21] involved the use of sera from animals immunized with sporozoites. [@B105] identified 16 previously uncharacterized pre-erythrocytic antigens ([@B105]), while the pre-erythrocytic MAEBL antigen was identified by [@B21].

CONCLUSION
==========

Historically, vaccine development efforts have been focused on immunodominant antigens as vaccine candidates such as merozoite or sporozoite surface proteins. However, the success has been limited thus far.

More recently, through the use of new technologies, immunoscreens have become more comprehensive, and has revealed the strong association of non-immunodominant malarial antigens with protection. Antigen libraries, expressed in bacterial, mammalian, or wheat germ cell-free expression systems, are created either as DNA libraries, recombinant proteins or on cell surface as antigen-presenting cells. In the screening of these antigen libraries for protective antigens, immune sera are an important tool. The type of immune sera chosen for the screening is critical. Carefully planned vaccination trials with an experimental challenge provide differential groups of sera from protected versus non-protected vaccinated individuals to identify protective antigens. Sera from chronically exposed individuals living in malaria-endemic regions have been also used in studies to screen for protective antigens. While sera from these individuals inform about naturally acquired immunity, it is essential to differentiate between the susceptible and the resistant individuals in these naturally exposed individuals. These differential sera allow the exclusion of immunodominant antigens, and inclusion of the non-immunodominant antigens that are associated with protection.

Taken together, the current consensus is protection against malaria is attributed to robust humoral responses directed against a panel of various non-variant antigens instead of only a single or a few immunodominant antigens. Studies to validate the feasibility of these minor non-immunodominant antigens as vaccine candidates should be prioritized for vaccine development against malarial infections. In addition, understanding antigen recognition is an essential step for the establishment of key immune correlates of protection against malarial infections, which would aid greatly in validating vaccine efficacy.
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